Cingulate® (CTx®) is a biopharmaceutical company focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders.
Cingulate® currently has two product candidates in pre-clinical development for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood.
The Precision Timed Release™ Platform
The Precision Timed Release™ Platform is a triad of proprietary, sophisticated elements
- Proprietary Erosion Barrier Layer (EBL)
- Specialized compression technology
- Semi-continuous manufacturing & real-time release
Computed Tomography Scan (CT scan) of CTx-1301 tablet